Home    Technology    Mission    People & Investors    News & Events    Products    Clinical Trials    Contact

Executive Team

PsiOxus Therapeutics has a highly experienced executive team.

Chief Executive Officer: Dr John Beadle

Dr John Beadle

Dr John Beadle was Entrepreneur in Residence at Imperial College London, where he helped to establish Myotec Therapeutics as a spin-out business. He became CEO of Myotec in late 2008, rapidly securing seed financing followed by a £5.6 million series A funding round from Imperial Innovations and Invesco Perpetual in early 2010. During this time, John was also Executive Chairman and CEO of Hybrid Biosystems, securing further seed financing for this Oxford based start-up. In 2010, John's leadership of these two private companies led to their combination to form PsiOxus Therapeutics Ltd. John was previously the co-founder of the vaccine company PowderMed. In 2004 he helped to raise £20 million from leading UK and US Venture Capital Funds and was then Chief Medical Officer and board director leading to the trade sale of PowderMed to Pfizer for over US$300 million in 2006. John has previously held roles at PowderJect, Pfizer and Glaxo SmithKline where he was most recently VP of Global Medical Operations. John was trained in Medicine at the University of Witwatersrand and received his MBA with distinction from the London Business School.

Chief Financial Officer and Company Secretary: Theodora Harold

Theodora Harold

Theodora Harold is a chartered accountant with significant experience as a Chief Financal Officer and Company Secretary with early stage and growing companies in the biotech sector. She has a background in both industry and corporate finance with 16 years of experience in SMEs in the biotech and hi-tech sectors and has held roles with Cytomyx Holdings plc, RioTech Pharmaceuticals Ltd, OrthoMimetics Ltd, Hybrid Biosystems Ltd, Myotec Therapeutics Ltd and Mission Therapeutics Ltd. Prior to this, Theodora trained with PricewaterhouseCoopers and read Classics at Trinity College, Cambridge.

Chief Operating Officer: Priya Mande

Priya Mande

Priya Mande has over 25 years' experience in the pharmaceutical and biotech sector, 12 of which were at Glaxo Wellcome and GlaxoSmithKline where she was most recently senior Director of R&D Business Projects.  She has held a variety of roles across research, development, project management, finance and business strategy & operations.  She was previously at PowderMed responsible for delivery of the vaccine immunotherapeutic portfolio.  Priya was the Vaccine Research Project Leader for Influenza at Pfizer before becoming Chief Operating Officer of Hybrid BioSystems in 2009.  Priya studied Applied Biochemistry at Brunel University, has a Diploma in Company Direction from the Institute of Directors and received her MBA with distinction from the London Business School.

Chief Medical Officer: Dr Hilary McElwaine-Johnn

Dr Hilary McElwaine-Johnn

Dr Hilary McElwaine-Johnn is a Physician with over 20 years' experience in drug development, most recently within venture capital backed biotech companies. Prior to joining PsiOxus in December 2015, Hilary was Chief Medical Officer at Vantia Therapeutics from 2008. Hilary has experience with small molecules and biologics across multiple phases of development in a broad range of therapeutic areas including immunotherapeutics and cancer vaccines. From 2004, Hilary was Vice President Clinical at PowerMed, responsible for clinical development of DNA based vaccines for influenza, chronic viral diseases and cancer, prior to its successful acquisition by Pfizer.

Hilary is a graduate of Imperial College London and St Mary's Hospital Medical School and is a Member of Royal College of Physicians and of the Faculty of Pharmaceutica Medicine.

Chief Scientific Officer: Dr Brian Champion

Dr Brian Champion

Dr Brian Champion was previously Executive Director and Head of Immunology for Pfizer's Vaccine Immunotherapeutics Research Unit in La Jolla, California. In this role Brian led the immunology team providing expertise and immunoassays for all Pfizer vaccine projects, including therapeutic T-cell focused vaccines for cancer, antibody focused vaccines for several different diseases as well as several prophylactic infectious disease vaccines. He was also a member of the leadership team as well as Program Lead for an anti-IgE therapeutic vaccine for allergy/asthma. Prior to this role, Brian was Site Head for Pfizer Vaccine Research in the UK. Before joining Pfizer, Dr Champion was Chief Scientific Officer for Lorantis and Celldex, Cambridge, developing protein and DNA-based, antigen-specific immunotherapeutic approaches to a variety of immunological diseases, including therapeutic vaccines and immunotherapeutic biomolecule approaches for cancer, infectious diseases, allergies and autoimmune disorders. Prior to Lorantis, he was with Glaxo and GlaxoWellcome (UK and USA) for 13 years, focusing primarily on target discovery and validation research for autoimmune, allergic and bone disorders

Executive Team

Dr John Beadle »
Theodora Harold »
Priya Mande »
Dr Hilary McElwaine-Johnn »
Dr Brian Champion »

Related Links

Board of Directors »
Scientific Advisory Board »
Executive Team »
Key Managers »
Investors and Shareholders »